

Estimate change

TP change

Rating change



Bloomberg	CEAT IN
Equity Shares (m)	40
M.Cap.(INRb)/(USDb)	120.3 / 1.4
52-Week Range (INR)	3263 / 2060
1, 6, 12 Rel. Per (%)	3/6/9
12M Avg Val (INR M)	684

**Financials & valuations (INR b)**

INR Billion	FY24	FY25E	FY26E
Sales	119.4	132.6	146.0
EBITDA	16.5	14.6	16.8
EBITDA Margin (%)	13.8	11.0	11.5
Adj. PAT	6.9	5.3	7.1
EPS (Rs)	169.4	131.9	176.3
EPS Growth (%)	226.6	-22.2	33.6
BV/Share (Rs)	999	1,106	1,248

**Ratios**

RoE (%)	18.3	12.5	15.0
RoCE (%)	15.3	11.7	13.3
Payout (%)	18.9	19.0	19.9

**Valuations**

P/E (x)	17.5	22.5	16.8
P/BV (x)	3.0	2.7	2.4
Div. Yield (%)	1.0	0.8	1.2
FCF Yield (%)	7.1	2.3	5.3

**Shareholding pattern (%)**

As On	Jun-24	Mar-24	Jun-23
Promoter	47.2	47.2	47.2
DII	17.1	15.9	12.2
FII	18.8	20.2	26.2
Others	16.9	16.7	14.4

FII includes depository receipts

**CMP: INR2,973 TP: INR3,450 (+16%)**
**BUY**
**Operating margins impacted by higher RM costs**
**Replacement and exports to drive growth, input cost to moderate in H2**

- Ceat Ltd (CEAT)'s 2QFY25 performance was impacted by higher RM costs, leading to a 100bp contraction in operating margins QoQ, which stood at 11% (est. 11.5%). The outlook for replacement segment across categories and exports remains healthy, with a recovery expected in the OEM segment in H2.
- CEAT's focus on strategic areas such as PVs/2Ws/OHT/exports (to help margins), along with prudent capex plans (to benefit FCF), should continue to improve its returns in the long run. Valuations at 22.5x/16.8x FY25E/FY26E consol. EPS appear reasonable. **We reiterate our BUY rating on the stock with a TP of INR3,450 (based on ~17x Sep'26E EPS).**

**Lower other expenses offset the impact of higher RM costs**

- CEAT's 2QFY25 revenue grew 8% YoY but EBITDA/adj. PAT declined 21%/41% YoY to INR3.6b/INR1.2b (est. INR3.8b/INR1.5b). 1HFY25 revenues grew 8.5% YoY but EBITDA/adj. PAT declined 12%/23% YoY. 2HFY25 revenue is estimated to grow 13.5% YoY while EBITDA/adj. PAT is estimated to decline 12%/21% YoY.
- Volume grew ~6.4% YoY, mainly led by double-digit growth in the replacement and exports markets, while OEM volumes experienced a 3-4% YoY decline.
- Gross margins contracted 590bp YoY (-180bp QoQ) to 37.4% (est.38.2%) due to the higher RM costs.
- EBITDA margin stood at 11% (-400bp YoY; est. 11.5%); the miss was mainly due to the higher RM costs, which were offset by savings in marketing costs, leading to lower other expenses.
- 1HFY25 cash outflow stood at INR114m (INR3.8b cash inflow in 1HFY24) due to the lower operating cash flow of INR4.15b (INR7.7b in 1HFY24) and higher capex of INR4.3b (INR3.9b in 1HFY24).
- Debt increased by INR2.4b sequentially to INR18.85b as of Sep'24. This was due to the higher WC requirement and payment of dividend. Capex stood at INR2.1b for the quarter.

**Highlights from the management commentary**

- **Outlook:** A double-digit volume growth is expected in replacement/export segments, with a bounce back in the OEM segment anticipated in H2.
- **RM costs are expected to witness a further rise (1.5-2%) in 3Q with some softening expected in 4Q.**
- **They have taken a price hike of 1.5%/3.5% in the first week of Oct'24.** They are looking to take further **price hikes in 3QFY25** to pass on the higher cost impact.
- The Sri Lanka business is recovering well and clocked 31% YoY volume growth in 2Q with 19.5% EBITDA margin.

Research analyst - Aniket Mhatre (Aniket.Mhatre@MotilalOswal.com)

Research analyst - Amber Shukla (Amber.Shukla@MotilalOswal.com) | Aniket Desai - (Aniket.Desai@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

 Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

**Valuation and view**

- CEAT has guided for double-digit volume growth in both replacement and export segments. It also expects OE demand to pick up in H2, led by new model wins and higher share of business in PVs/2Ws/CVs. However, given the rising cost pressure, we have lowered our FY25/FY26 EPS estimate by 9% each.
- CEAT's focus on strategic areas such as PVs/2Ws/OHT/exports (to help margins), along with prudent capex plans (to benefit FCF), should continue to improve its returns in the long run. Valuations at 22.5x/16.8x FY25E/FY26E consol. EPS appear reasonable. **We reiterate our BUY rating on the stock with a TP of INR3,450 (based on ~17x Sep'26E EPS).**

**Consolidated - Quarterly Earning Model**

(INR m)

Y/E March	FY24				FY25E				FY24	FY25E	
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE
<b>Net Sales</b>	<b>29,352</b>	<b>30,533</b>	<b>29,631</b>	<b>29,919</b>	<b>31,928</b>	<b>33,045</b>	<b>33,780</b>	<b>33,822</b>	<b>1,19,435</b>	<b>1,32,576</b>	<b>32,976</b>
YoY Change (%)	4.1	5.5	8.7	4.1	8.8	8.2	14.0	13.0	5.6	11.0	8.0
RM Cost (%)	58.9	56.7	58.7	57.7	60.8	62.6	63.0	62.5	58.0	62.2	61.8
Employee Cost (%)	6.7	7.1	7.3	7.2	6.1	6.6	6.3	6.5	7.1	6.4	6.1
Other Expenses (%)	21.2	21.3	19.9	22.0	21.1	19.8	20.2	20.5	21.1	20.4	20.6
<b>EBITDA</b>	<b>3,871</b>	<b>4,561</b>	<b>4,175</b>	<b>3,915</b>	<b>3,829</b>	<b>3,623</b>	<b>3,547</b>	<b>3,552</b>	<b>16,522</b>	<b>14,550</b>	<b>3,792</b>
Margins (%)	13.2	14.9	14.1	13.1	12.0	11.0	10.5	10.5	13.8	11.0	11.5
Depreciation	1,209	1,245	1,273	1,361	1,318	1,371	1,380	1,388	5,088	5,457	1,320
Interest	701	717	656	617	619	665	600	551	2,691	2,434	550
Other Income	33	105	29	31	62	35	70	114	197	280	75
<b>PBT Before EO Expense</b>	<b>1,993</b>	<b>2,704</b>	<b>2,276</b>	<b>1,969</b>	<b>1,954</b>	<b>1,622</b>	<b>1,637</b>	<b>1,726</b>	<b>8,941</b>	<b>6,939</b>	<b>1,997</b>
Exceptional Item	0	0	0	582	-75	0	0	74	582	0	0
<b>PBT</b>	<b>1,993</b>	<b>2,704</b>	<b>2,276</b>	<b>1,387</b>	<b>2,029</b>	<b>1,621</b>	<b>1,637</b>	<b>1,652</b>	<b>8,359</b>	<b>6,939</b>	<b>1,997</b>
Tax Rate (%)	26.5	25.3	23.9	33.0	26.6	28.6	26.0	22.7	26.5	26.0	26.0
Minority Int. & Profit of Asso. Cos.	18	-59	-84	-157	-53	-61	-55	-32	-282	-200	-45
<b>Reported PAT</b>	<b>1,446</b>	<b>2,080</b>	<b>1,815</b>	<b>1,086</b>	<b>1,542</b>	<b>1,219</b>	<b>1,266</b>	<b>1,308</b>	<b>6,427</b>	<b>5,335</b>	<b>1,523</b>
<b>Adj PAT</b>	<b>1,446</b>	<b>2,080</b>	<b>1,815</b>	<b>1,513</b>	<b>1,486</b>	<b>1,219</b>	<b>1,266</b>	<b>1,363</b>	<b>6,854</b>	<b>5,335</b>	<b>1,523</b>
YoY Change (%)	1,383	745	408	8	3	-41	-30	-10	227	-22	-26.8

**Key Performance Indicators**

RM Cost (% of sales)	58.9	56.7	58.7	57.7	60.8	62.6	63.0	62.5	58.0	62.2	61.8
Staff Cost (% of sales)	6.7	7.1	7.3	7.2	6.1	6.6	6.3	6.5	7.1	6.4	6.1
Other Cost (% of sales)	21.2	21.3	19.9	22.0	21.1	19.8	20.2	20.5	21.1	20.4	20.6
Gross Margin (%)	41.1	43.3	41.3	42.3	39.2	37.4	37.0	37.5	41.1	43.3	38.2
EBITDA Margins (%)	13.2	14.9	14.1	13.1	12.0	11.0	10.5	10.5	13.8	11.0	11.5
EBIT Margins (%)	9.1	10.9	9.8	8.5	7.9	6.8	6.4	6.4	13.8	11.0	7.5

E:MOFSL Estimates



## Highlights from the management commentary

### Domestic business updates:

- **Outlook:** A double digit growth is expected in the replacement/export segments, with a bounce back anticipated in the OEM segment in H2. OEM's revival is expected due to new launches in PVs/2Ws and CEAT's growing share of business with OEMs. The enhanced capacity of TBR facility will also aid in the company's growth. Better availability of containers is likely to help improve exports in H2.
- **2QFY25 volumes grew 6.4% YoY (+1.2% QoQ):** Replacement and export volumes grew double digit on a YoY basis while OEMs experienced a 3-4% YoY decline.
  - In the replacement segment, TBR/PCR/2Ws grew in double digits while TBB/LCVs declined. The OHT segment grew in low single digit. It is gaining market share in the TBR segment due to superior products and market wins in some parts of the country. PV replacement is benefiting from its tire brands such as Cross Drive and Sports Drive in premium segments.
- **RM costs to witness a further rise (1.5-2%) in 3Q with some softening expected in 4Q:** The commodity basket grew ~6% sequentially. Domestic NR prices stood at INR250/kg in 2Q, which was INR50/kg more than the international rubber prices. Currently, domestic NR prices have experienced some softening, but imported rubber prices have started inching up. CEAT expects the RM basket to remain at elevated levels in 3Q, partly due to its older high-cost inventory. Hence, it is expected to witness a further inflation of 1.5-2% in Q3.
- **Price hikes implemented in 2Q, with more to follow in 3Q:** The company experienced a price hike of 1-2% in CVs, 1.5% in PVs, and 2% in the rest of the categories in Q2. In the first week of October, it implemented another price hike of 1.5%/3.5% in CVs/PVs. It is also contemplating price hikes during Nov-Dec in 2Ws/TBB and other categories. It has received a price indexation benefit of 3% in 2Q (for 1Q) from OEMs and is expected to receive an additional 4% in 3Q (for 2Q).

### Export business updates:


- **2QFY25 experienced double-digit volume growth, which was limited by the Red Sea crisis.** Freight rates remained high during the quarter, indicating signs of cooling. The top three clusters continue to remain EU/ LatAm/Middle East, contributing ~65% of CEAT's exports. It has commenced TBR production from the Chennai plant, which will mainly cater to the EU and US markets. The capacity from the plant stands at 45k tires/month.
- The Sri Lankan business is recovering well and clocked 31% YoY volume growth in 2Q with a 19.5% EBITDA margin.
- Agri radials continue to experience headwinds in terms of end markets and have been flat on a YoY basis, mainly due to a decline in OEMs (down 50-60% YoY), which is offset by the growth of the replacement market. There has been inventory build-up and macro remains weak. While the inventory situation is normalizing, demand is likely to take a few more quarters to recover.
- CEAT has been launching 40+ SKUs every quarter in the agri-radial segments. It has received approvals from two OEM customers (Massey Fergusson in France and CFI in the US) for supply. It will be launching 30-40/8-10 SKUs in PVs/TBR over the next two quarters.
- The company is also focusing on exporting PCR tires to OEMs, but it will still take 2-4 years to obtain their approval. Hence, it will be focusing on the replacement market for the PVs and TBR segments.

**Other business updates:**

- The overall capacity utilization stands at around 80%.
- CEAT continues to be the leading player in 2Ws with about 35% market share. Its market share in PCR stands at 17%. It ranks a close third in this segment with an aspiration to reach the leadership position over the next two to three years. Further, it has a 30% market share in e-2Ws and 25% in e-PVs.
- Other expenses were lower by INR240m sequentially, mainly due to lower marketing costs. Employee costs were higher 12% sequentially on account of annual increments.
- The company has maintained its full-year capex guidance at INR10-10.5b (INR4.3b already spent in 1H).
- Its debt increased by INR2.4b due to higher working capital requirements as against Q1FY25 and the payment of dividends (INR1.2b). Debt/EBITDA stood at 1.19 and D/E at 0.45 at the end of Sep'24. It is currently comfortable with the current leverage ratios.
- The formation of the Indonesian subsidiary is mainly to explore opportunities; the company does not intend to set up any manufacturing facility there.


## Key exhibits

**Exhibit 1: Trend in revenue**




Source: MOFSL, Company

**Exhibit 2: Trend in gross margin**




Source: MOFSL, Company

**Exhibit 3: EBITDA and EBITDA margin trends**



Source: MOFSL, Company

**Exhibit 4: Absolute PAT trend**



Source: MOFSL, Company


## Valuation and view

- Focus on improving brand equity to drive market share gains:** CEAT has placed a strong emphasis on effective marketing and branding (~2.0-2.5% of sales) for its products. To position its products competitively, it has developed creative advertising campaigns based on research and consumer insights and has invested in innovative marketing programs. Since the 2W and Passenger Car segments are consumer-facing, factors such as brand loyalty, visibility, and recall play a significant role in creating replacement market demand and improving market share. This, in turn, would benefit its margin profile.
- Ramp-up in strategic focus areas to continue:** Management has identified the 2W, Passenger Car, and OTR (truck/off-road) tire segments as strategic focus areas, given their abilities to boost margin and lower CEAT's dependence on the Truck segment. Revenue contribution from these focus areas has surged over the years (to 62% in FY24 from mere 20% in FY10). This is also reflected in the market share gain in the PCR segment (over 17% now from 11% a few years back). Even in the 2W replacement segment, CEAT continues to enjoy a very high market share of 35% currently. Moreover, it has ramped up its presence in EVs with a current market share of 30% in 2Ws and 20% in PVs.


- **Healthy growth outlook mainly led by replacement demand:** Given a balanced presence across key segments, management expects steady growth from most of these segments: 1) strong volume growth from the TBR replacement segment; 2) steady PCR volume growth; 3) the 2W segment growth expected mainly from small towns; 4) **OEMs:** likely revival from all segments, mainly on account of new order wins and higher share of business with existing customers, and 5) export contribution to increase to 25% in the next couple of years from 19% currently, backed by its recent initiatives. Overall, management expects replacement demand to grow in double digits in FY25E. It also expects to manage the EPR impact through a combination of price hikes and improved mix. Accordingly, we expect CEAT to clock a revenue/EBITDA/PAT CAGR of ~11%/1%/2% over FY24-26.
- **Valuation and view:** A stable growth outlook for domestic OEMs and a pick-up in replacement demand will enable a faster absorption of new capacities and drive operating leverage benefits. Factoring in the rising RM costs, we have cut our FY25E/FY26E EPS by 9% each. CEAT's focus on strategic areas such as PV/2W/OHT/exports (to help margins), along with prudent capex plans (to benefit FCF), should continue to improve its returns in the long run. Valuations are at 22.5x/16.8x FY25E/FY26E consol. EPS appears reasonable. **Hence, we reiterate our BUY rating on the stock with a TP of INR3,450 (based on ~17x Sep'26E EPS).**

**Exhibit 5: Changes to our estimates**

(INR M)	FY25E			FY26E		
	Rev	Old	Chg (%)	Rev	Old	Chg (%)
Net Sales	1,32,576	1,30,641	1.5	1,46,045	1,43,915	1.5
EBITDA	14,550	14,893	-2.3	16,795	16,982	-1.1
EBITDA (%)	11.0	11.4	-40bp	11.5	11.8	-30bp
Adj. PAT	5,335	5,864	-9.0	7,129	7,824	-8.9
EPS (INR)	131.9	145.0	-9.0	176.3	193.4	-8.9

**Exhibit 6: One-year forward P/E**


Source: MOFSL, Company

**Exhibit 7: One-year forward P/B band**

Source: MOFSL, Company


## Story in charts

**Exhibit 8: Revenue and growth trends**




Source: MOFSL, Company

**Exhibit 9: Key revenue segments**




Source: MOFSL, Company

**Exhibit 10: EBITDA and EBITDA margin trends**




Source: MOFSL, Company

**Exhibit 11: PAT and PAT growth trends**




Source: MOFSL, Company

**Exhibit 12: Trend in debt levels**



Source: MOFSL, Company

**Exhibit 13: Trend in return profile**



Source: MOFSL, Company



## Financials and valuations

### Consolidated - Income Statement

(INR m)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
<b>Net Revenues from Ops</b>	<b>67,788</b>	<b>76,096</b>	<b>93,634</b>	<b>1,13,149</b>	<b>1,19,435</b>	<b>1,32,576</b>	<b>1,46,045</b>	<b>1,62,373</b>
Change (%)	-2.9	12.3	23.0	20.8	5.6	11.0	10.2	11.2
<b>EBITDA</b>	<b>7,238</b>	<b>9,830</b>	<b>7,098</b>	<b>9,738</b>	<b>16,522</b>	<b>14,550</b>	<b>16,795</b>	<b>19,485</b>
EBITDA Margin (%)	10.7	12.9	7.6	8.6	13.8	11.0	11.5	12.0
Depreciation	2,765	3,396	4,352	4,693	5,088	5,457	5,871	6,172
<b>EBIT</b>	<b>4,473</b>	<b>6,433</b>	<b>2,746</b>	<b>5,045</b>	<b>11,434</b>	<b>9,093</b>	<b>10,925</b>	<b>13,313</b>
EBIT Margin (%)	6.6	8.5	2.9	4.5	9.6	6.9	7.5	8.2
Int. and Finance Charges	1,509	1,755	2,070	2,421	2,691	2,434	1,988	1,468
Other Income	205	138	114	169	197	280	400	400
<b>PBT bef. EO Exp.</b>	<b>3,169</b>	<b>4,816</b>	<b>790</b>	<b>2,793</b>	<b>8,941</b>	<b>6,939</b>	<b>9,337</b>	<b>12,245</b>
EO Items	5	-341	-129	-334	-582	0	0	0
<b>PBT after EO Exp.</b>	<b>3,174</b>	<b>4,476</b>	<b>661</b>	<b>2,459</b>	<b>8,359</b>	<b>6,939</b>	<b>9,337</b>	<b>12,245</b>
Total Tax	1,046	516	243	718	2,214	1,804	2,428	3,184
Tax Rate (%)	33.0	11.5	36.7	29.2	26.5	26.0	26.0	26.0
Minority Int./Share JV PAT	-184	-361	-294	-120	-282	-200	-220	-220
<b>Reported PAT</b>	<b>2,312</b>	<b>4,320</b>	<b>712</b>	<b>1,862</b>	<b>6,427</b>	<b>5,335</b>	<b>7,129</b>	<b>9,281</b>
<b>Adjusted PAT</b>	<b>2,309</b>	<b>4,622</b>	<b>794</b>	<b>2,098</b>	<b>6,854</b>	<b>5,335</b>	<b>7,129</b>	<b>9,281</b>
Change (%)	-14.7	100.2	-82.8	164.4	226.6	-22.2	33.6	30.2
Margin (%)	3.4	6.1	0.8	1.9	5.7	4.0	4.9	5.7

### Consolidated - Balance Sheet

(INR m)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Equity Share Capital	405	405	405	405	405	405	405	405
Total Reserves	28,675	32,758	32,324	33,992	40,022	44,345	50,059	57,520
<b>Net Worth</b>	<b>29,079</b>	<b>33,163</b>	<b>32,728</b>	<b>34,396</b>	<b>40,426</b>	<b>44,749</b>	<b>50,463</b>	<b>57,924</b>
Minority Interest	237	232	235	174	97	97	97	97
Total Loans	18,772	14,176	20,968	20,927	16,289	17,289	13,289	9,289
Deferred Tax Liabilities	2,744	2,800	3,177	3,886	4,245	4,245	4,245	4,245
<b>Capital Employed</b>	<b>50,832</b>	<b>50,371</b>	<b>57,108</b>	<b>59,383</b>	<b>61,057</b>	<b>66,381</b>	<b>68,094</b>	<b>71,555</b>
Gross Block	49,795	58,732	67,748	80,110	86,717	96,717	1,05,717	1,14,717
Less: Accum. Depn.	8,197	11,097	14,456	19,149	24,237	29,694	35,565	41,737
<b>Net Fixed Assets</b>	<b>41,598</b>	<b>47,634</b>	<b>53,292</b>	<b>60,961</b>	<b>62,480</b>	<b>67,023</b>	<b>70,152</b>	<b>72,980</b>
Goodwill on Consolidation	0	0	0	0	231	231	231	231
Capital WIP	10,685	7,929	8,759	5,961	6,835	6,835	6,835	6,835
<b>Total Investments</b>	<b>1,837</b>	<b>2,101</b>	<b>1,792</b>	<b>1,696</b>	<b>1,821</b>	<b>1,821</b>	<b>1,821</b>	<b>4,021</b>
<b>Curr. Assets, Loans &amp; Adv.</b>	<b>19,410</b>	<b>23,087</b>	<b>27,176</b>	<b>27,519</b>	<b>28,314</b>	<b>36,517</b>	<b>39,601</b>	<b>43,496</b>
Inventory	9,257	11,299	13,096	11,378	11,505	16,168	17,706	19,574
Account Receivables	6,744	9,216	11,543	13,070	12,832	16,345	18,006	20,019
Cash and Bank Balance	342	431	363	719	591	1,352	969	656
Loans and Advances	3,067	2,141	2,174	2,353	3,386	2,652	2,921	3,247
<b>Curr. Liability &amp; Prov.</b>	<b>22,697</b>	<b>30,380</b>	<b>33,910</b>	<b>36,754</b>	<b>38,623</b>	<b>46,046</b>	<b>50,546</b>	<b>56,008</b>
Account Payables	11,948	18,395	21,576	22,683	23,321	27,485	30,099	33,275
Other Current Liabilities	9,114	10,444	10,654	12,154	13,462	15,909	17,525	19,485
Provisions	1,635	1,541	1,680	1,917	1,840	2,652	2,921	3,247
<b>Net Current Assets</b>	<b>-3,288</b>	<b>-7,293</b>	<b>-6,734</b>	<b>-9,234</b>	<b>-10,310</b>	<b>-9,529</b>	<b>-10,945</b>	<b>-12,512</b>
<b>Appl. of Funds</b>	<b>50,832</b>	<b>50,371</b>	<b>57,108</b>	<b>59,383</b>	<b>61,057</b>	<b>66,381</b>	<b>68,094</b>	<b>71,555</b>



## Financials and valuations

### Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
<b>Basic (INR)</b>								
<b>EPS</b>	<b>57.1</b>	<b>114.3</b>	<b>19.6</b>	<b>51.9</b>	<b>169.4</b>	<b>131.9</b>	<b>176.3</b>	<b>229.5</b>
Cash EPS	125.4	198.2	127.2	167.9	295.2	266.8	321.4	382.0
BV/Share	718.9	819.8	809.1	850.3	999.4	1,106.3	1,247.5	1,432.0
DPS	12.0	18.0	3.0	12.0	30.0	25.0	35.0	45.0
Payout (%)	25.3	16.9	17.0	26.1	18.9	19.0	19.9	19.6
<b>Valuation (x)</b>								
P/E	52.0	26.0	151.3	57.2	17.5	22.5	16.8	12.9
Cash P/E	23.7	15.0	23.3	17.7	10.1	11.1	9.2	7.8
P/BV	4.1	3.6	3.7	3.5	3.0	2.7	2.4	2.1
EV/Sales	2.0	1.8	1.5	1.2	1.1	1.0	0.9	0.8
EV/EBITDA	19.1	13.6	19.8	14.4	8.2	9.3	7.9	6.6
Dividend Yield (%)	0.4	0.6	0.1	0.4	1.0	0.8	1.2	1.5
<b>Return Ratios (%)</b>								
RoE	8.1	14.9	2.4	6.3	18.3	12.5	15.0	17.1
RoCE (Post Tax)	7.0	12.2	3.6	6.8	15.3	11.7	13.3	15.5
RoIC	8.4	14.6	4.0	7.4	16.3	12.4	14.1	16.6
<b>Working Capital Ratios</b>								
Fixed Asset Turnover (x)	1.4	1.3	1.4	1.4	1.4	1.4	1.4	1.4
Asset Turnover (x)	1.3	1.5	1.6	1.9	2.0	2.0	2.1	2.3
Inventory (Days)	50	54	51	37	35	45	44	44
Debtor (Days)	36	44	45	42	39	45	45	45
Creditor (Days)	64	88	84	73	71	76	75	75
<b>Leverage Ratio (x)</b>								
Current Ratio	0.9	0.8	0.8	0.7	0.7	0.8	0.8	0.8
Interest Cover Ratio	3.0	3.7	1.3	2.1	4.2	3.7	5.5	9.1
Net Debt/Equity	0.6	0.4	0.6	0.6	0.4	0.4	0.2	0.1

### Consolidated - Cash Flow Statement

(INR m)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
OP/(Loss) before Tax	2,871	4,476	661	2,459	8,359	6,939	9,337	12,245
Depreciation	2,765	3,396	4,352	4,693	5,088	5,457	5,871	6,172
Interest & Finance Charges	1,509	1,755	2,070	2,421	2,691	2,154	1,588	1,068
Direct Taxes Paid	-181	-512	-200	377	-1,630	-1,804	-2,428	-3,184
(Inc)/Dec in WC	2,582	4,516	-736	2,211	2,674	-19	1,032	1,254
<b>CF from Operations</b>	<b>9,546</b>	<b>13,631</b>	<b>6,147</b>	<b>12,161</b>	<b>17,183</b>	<b>12,727</b>	<b>15,400</b>	<b>17,555</b>
Others	17	-54	42	-106	10	0	0	0
<b>CF from Operating incl EO</b>	<b>9,563</b>	<b>13,577</b>	<b>6,189</b>	<b>12,055</b>	<b>17,193</b>	<b>12,727</b>	<b>15,400</b>	<b>17,555</b>
(Inc)/Dec in FA	-11,183	-6,395	-9,558	-8,779	-8,668	-10,000	-9,000	-9,000
<b>Free Cash Flow</b>	<b>-1,620</b>	<b>7,182</b>	<b>-3,369</b>	<b>3,276</b>	<b>8,525</b>	<b>2,727</b>	<b>6,400</b>	<b>8,555</b>
(Pur)/Sale of Investments	9	-27	-89	-11	-47	0	0	-2,200
Others	419	241	203	299	178	280	400	400
<b>CF from Investments</b>	<b>-10,755</b>	<b>-6,181</b>	<b>-9,444</b>	<b>-8,491</b>	<b>-8,537</b>	<b>-9,720</b>	<b>-8,600</b>	<b>-10,800</b>
Issue of Shares	0	0	0	0	0	0	0	0
Inc/(Dec) in Debt	3,854	-5,677	5,821	-41	-4,638	1,000	-4,000	-4,000
Interest Paid	-1,925	-1,628	-1,944	-2,093	-2,669	-2,434	-1,988	-1,468
Dividend Paid	-1,139	-4	-746	-126	-485	-1,011	-1,416	-1,820
Others	0	0	0	-936	-918	200	220	220
CF from Fin. Activity	790	-7,309	3,132	-3,195	-8,710	-2,246	-7,183	-7,068
<b>Inc/Dec of Cash</b>	<b>-402</b>	<b>87</b>	<b>-123</b>	<b>368</b>	<b>-55</b>	<b>762</b>	<b>-384</b>	<b>-313</b>
Opening Balance	675	274	361	238	606	552	1,313	929
<b>Closing Balance</b>	<b>274</b>	<b>361</b>	<b>238</b>	<b>606</b>	<b>552</b>	<b>1,313</b>	<b>929</b>	<b>617</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.